Scribe Therapeutics, Inc.
7.30%
1,388,161
1853921
Jul 22, 2026
Jul 30, 2026, 04:39 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| ELI LILLY & Co | CO | 7.30% | 1,388,161 | 1,388,161 | 0 |
Disclosure Items (7)
Common stock, $0.001 par value per share
Scribe Therapeutics, Inc.
1150 MARINA VILLAGE PKWY, ALAMEDA, CA, 94501
Eli Lilly and Company
Lilly Corporate Center Indianapolis, Indiana 46285
The principal business of Eli Lilly and Company is the discovery, development, manufacturing, marketing and sale of pharmaceutical products worldwide. The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
During the last five years, neither the Reporting Person nor, to the knowledge of the Reporting Person, any of the persons listed on Schedule A attached hereto, have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Indiana
The Reporting Person beneficially owns an aggregate of 1,388,161 shares of Common Stock of the Issuer, consisting of (a) 1,054,828 shares of Common Stock that were issued on July 10, 2026 to the Reporting Person upon conversion of the Issuer's 8% Convertible Promissory Note ("Promissory Note") previously acquired for an aggregate purchase price of $30.0 million; and (b) 333,333 shares of Common Stock purchased by the Reporting Person in the IPO at the public offering price of $15.00 per share, for an aggregate purchase price of approximately $5.0 million. The funds used by the Reporting Person to acquire the Promissory Note and the Common Stock purchased in the IPO consisted of cash on hand.
The Reporting Person directly holds an aggregate of 1,388,161 shares of Common Stock, representing approximately 7.36% of the issued and outstanding shares of Common Stock. Ownership percentages set forth in this Schedule 13D are based upon a total of 18,864,386 shares of Common Stock outstanding as of July 27, 2026, following the consummation of the Issuer's IPO as described in its Prospectus filed under Rule 424(b)(4) of the Securities Act of 1933, as amended, on July 27, 2026, after giving effect to the full exercise of the underwriters' option to purchase an additional 1,287,000 shares of Common Stock, as disclosed in the press release issued by the Issuer on July 27, 2026.
The information included in part (a) of Item 5 above is incorporated by reference herein.
Other than as described in Item 3, the Reporting Person has not purchased or sold any shares of Common Stock during the past 60 days.
No other person is known by the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Person.
N/A
Lock-Up Agreement The Reporting Person has entered into a lock-up agreement pursuant to which the Reporting Person has agreed not to, among other things and subject to various exceptions, sell or transfer Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for 180 days after July 23, 2026 without first obtaining the prior written consent of Leerink Partners LLC and Goldman Sachs & Co. LLC on behalf of the underwriters. The foregoing description of the lock-up agreement does not purport to be complete and is qualified in its entirety by reference to the form of lock-up agreement, listed as Exhibit 2.1 hereto and incorporated by reference herein.
Exhibit 2.1: Form of Lock-Up Agreement (Incorporated by reference to the Form of the Lock-Up Agreement attached as Annex II to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1 (SEC File No. 333-297246), filed with the Securities and Exchange Commission on July 20, 2026).